|
新闻
Biodel Inc. Announces Completion of Public Offering
DANBURY, Conn., May 17 /PRNewswire-FirstCall/ - Biodel Inc. (Nasdaq: BIOD) today announced it has
completed its initial public offering. Biodel sold a total of 5,750,000
shares of its common stock, which included 750,000 shares sold upon the
exercise by the underwriters of an over-allotment option, at a price to
the public of $15.00 per share. The offering resulted in gross proceeds
to Biodel of $86,250,000 and, after underwriting discounts, net proceeds
of $80,212,500.
Morgan Stanley & Co. Incorporated acted as the sole
book-runner and lead manager in the offering, Banc of America Securities
LLC as co-lead manager, and Leerink Swann & Co., Inc. and Natexis
Bleichroeder Inc. as co-managers in the offering.
Biodel is a specialty
pharmaceutical company focused on the development and commercialization
of innovative treatments for endocrine disorders such as diabetes and
osteoporosis.
Vivo Ventures co-led the first institutional financing for the company.
« 回 新闻
|
